This report on global antibacterial drugs market studies various drug classes used for treatment of bacterial infections along with pipeline analysis of upcoming potential drugs. Bacterial infection, irrespective of its etiology is an important concern in patients with cirrhosis since it is associated with increased morbidity and mortality. According to World Health Organization (WHO), cirrhotic patients from developed countries indicate urinary tract infections (12 – 29%) to be the most frequent cause for bacterial sepsis followed by spontaneous bacterial peritonitis (15 – 23%), respiratory tract infection (6 – 10%) and bacteremia (4-9%).
For the purpose of this study, the various drug classes studied include aminoglycosides, beta-lactams, tetracyclines, sulfonamides, quinolones, macrolides, phenicols and miscellaneous antibacterials.
The pipeline analysis for antibacterial drugs market comprises projected market sales of Phase III drugs estimated till 2029. The phase III drugs included in the pipeline analysis are solithromycin (Cempra, Inc.), VivaGel/ SPL7013 (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & Co.) and others. The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.
The geographic segmentation of the global antibacterial drugs market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries.
According to market stakeholders, bacterial infections cause an enormous financial and physical burden of disease throughout the globe and kill millions of humans and animals. A few most common bacterial infections are pneumonia, diarrhea and meningitis, genito-urinary infections and blood infections. Recently hospital acquired diseases such as tuberculosis, pneumonia, and others are on the rise in many parts of the world. Resistance to antibiotics is now widespread among bacteria and is increasing at an alarming rate.
In base year 2021, beta-lactams accounted for the largest market share of 55.8% of the global antibacterial drugs market followed by the quinolones. In the near future these drug classes are expected to experience a decline in their market share during the forecast period 2016 to 2029 because leading brands will lose their market exclusivity, coupled with high rate of clinical trial failures, rising number of drug resistant bacterial strains and high influx of generic drugs. Thus, on the basis of the factors mentioned above, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2023 to 2030. Although, the miscellaneous antibacterial drug class is expected to project noticeable growth along with rising demand for novel therapies against bacterial infections and aging population.
In base year 2021, it was observed that Asia Pacific dominated the overall market and is also projected to witness the fastest growth during the forecast period 2020 - 2030. The key factors assisting the growth of Asia Pacific antibacterial drugs market are it accounts for the largest infected population in the world with a variety of bacterial infections such as pneumonia, tuberculosis and tetanus, presence of large number of manufacturers of active pharmaceutical ingredient and generic drugs, high disposable income, rising geriatric population, and emerging healthcare infrastructure. North America, followed by Europe, is the second largest antibacterial drugs market globally in terms of revenue. North America and Europe are anticipated to witness slow growth over the forecast period due to stringent regulatory policies, abridged product lifecycle, and generic penetration.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Antibacterial Drugs market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Drug Class
| |
Routes of Administration
| |
Channels of Distribution
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
